Nutrition review proposes calorie floors during GLP-1 and dual incretin therapy
The framework sets proposed minimum calorie levels for adults on GLP-1 and dual incretin drugs, plus guidance on managing side effects and keeping weight off.
A review published in the journal Nutrients proposes a nutrition-first framework for people using GLP-1 and dual incretin therapy for obesity. It includes suggested energy floors of roughly 1,200 calories a day for most women and 1,500 calories a day for most men, adjusted for body size and activity [1].
The article is titled "Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance" [1]. It appears in volume 18, issue 11 of Nutrients, an open-access journal, as article 1751, with the DOI 10.3390/nu18111751 [1].
What the framework covers
The title names three areas: how people on these drugs eat, how well they tolerate the medication's side effects, and how they maintain weight loss over time [1]. The calorie figures are presented as floors rather than targets, meaning the authors describe them as minimum levels that should be adjusted for a person's body size and how active they are [1].
Nutrients labels the article as a review, meaning it pulls together and organizes existing information rather than reporting results from a new clinical trial [1].
The authors are Raynier Zambrano-Villacres, Martín Campuzano-Donoso, Claudia Reytor-González, Gianluca Rossetti, Luigi Cobellis, Vincenzo Pilone, Daniel Simancas-Racines and Luigi Schiavo [1]. The academic editor listed for the article is Antonio Cepeda-Benito [1]. The journal page lists the article in PubMed/Medline under ID 42280393 and shows an Altmetric score of 4 [1].
Why it matters for patients
Appetite loss is the point of GLP-1 and dual incretin therapy, but it can make it hard to take in enough food overall. The framework's central idea is that nutrition support should come first, alongside the medication, rather than being added only after problems appear [1].
The calorie floors give patients and their clinicians a concrete reference point for a question that comes up often on these drugs: how little is too little. The authors frame the numbers as individualized, so they are not a single cutoff that applies to everyone [1].
The third piece of the framework, long-term weight maintenance, addresses a period when many people's eating patterns change again. Whether someone continues, pauses or stops medication, the review treats maintenance as a phase that needs its own nutritional plan rather than an afterthought [1].
It is worth being precise about what this article is. It is a proposed framework in a peer-reviewed journal, not a set of clinical practice guidelines and not a report of patient outcomes. How the proposed floors perform in practice, and whether they change weight or side-effect outcomes, is not established in the article [1].
What happens next
No follow-up trial, guideline endorsement or implementation study tied to the framework is described on the article page [1]. Whether the proposed energy floors will be tested against other approaches, and whether medical societies will adopt or revise them, has not been reported [1]. The article page also does not list specific products, brand names or doses for the medications discussed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.